Summary of Significant Accounting Policies - Additional Information (Details)	3 Months Ended		12 Months Ended
	Dec. 31, 2024 USD ($)	Dec. 31, 2023 USD ($)	Dec. 31, 2025 USD ($) Segment	Dec. 31, 2024 USD ($)	Dec. 31, 2023 USD ($)	Feb. 28, 2019 USD ($)
Summary Of Significant Accounting Policies [Line Items]
Off-balance sheet concentrations of credit risk, description			The Company has no off-balance sheet concentrations of credit risk, such as foreign currency exchange contracts, option contracts, or other hedging arrangements.
Impairment of long-lived assets			$ 44,611,000	$ 1,891,000	$ 7,014,000
Asset Impairment Charges			44,611,000	1,891,000	7,014,000
Research and development expenses			131,980,000	215,673,000	$ 261,809,000
Goodwill	$ 140,627,000		140,627,000	140,627,000
Amortization of intangible asset			$ 0
Impairments of intangible asset				$ 0
Expected dividend yield			0.00%	0.00%	0.00%
Number of operating segment | Segment			1
Lab Equipment and Leasehold Improvements
Summary Of Significant Accounting Policies [Line Items]
Asset Impairment Charges	$ 1,900,000	$ 7,000,000
Acquisition Agreement | Cobalt Biomedicine, Inc
Summary Of Significant Accounting Policies [Line Items]
Goodwill			$ 140,600,000			$ 140,600,000
Impairments of goodwill			$ 0
Minimum
Summary Of Significant Accounting Policies [Line Items]
Property and equipment, estimated useful life			3 years
Maximum
Summary Of Significant Accounting Policies [Line Items]
Property and equipment, estimated useful life			5 years